会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • SPIRO (PIPERIDINE-4, 2 ' -PYRROLIDINE) -1- (3, 5- TRIFLUOROMETHYL PHENYL) METHYLCARBOXAMIDES AS NK1 TACHIKYNIN RECEPTOR ANTAGONISTS
    • 作为NK1 TACHIKYNIN受体拮抗剂的SPIRO(哌啶-4,2'-吡咯烷)-1-(3,5-二氟甲基苯基)甲基氨基甲酰胺
    • WO2009133135A1
    • 2009-11-05
    • PCT/EP2009/055190
    • 2009-04-29
    • GLAXO WELLCOME MANUFACTURING PTE LTDALVARO, GiuseppeCASTIGLIONI, EmilianoMARASCO, Agostino
    • ALVARO, GiuseppeCASTIGLIONI, EmilianoMARASCO, Agostino
    • C07D471/10C07D498/20A61P25/22A61P25/24A61P29/00
    • C07D471/10C07D498/20
    • Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R is hydrogen or C 1-4 alkyl; R 1 is hydrogen, C 1-4 alkyl, C(O)OH, C(O)NH 2 or (C 1-4 alkylene)R 10 ; R 2 and R 3 are independently hydrogen, C 1-4 alkyl or R 2 together with R 3 and together with the carbon atom to which they are attached form a C 3-8 cycloalkyl group; R 4 is C 1-4 alkyl, C 1-4 alkoxy or halogen; R 5 and R 7 are independently hydrogen, hydroxy, halogen, C(O)NH 2 , C(O)OH or (C 1-4 alkylene) R 10 ; R 6 and R 8 are independently hydrogen or halogen; R 9 is hydrogen, (C 1-4 alkylene)R 10 , C(O)NH 2 , C(O)OH or R 9 together with R form a 6 membered heterocyclic ring optionally containing a further heteroatom selected from oxygen, sulphur or nitrogen; R 10 is hydrogen, halogen, hydroxy, C(O)NH 2 , C(O)NH(C 1-4 alkyl), C(O)N(C 1-4 alkyl) 2 or C(O)OH; n is O, 1 or 2. processes for their preparation, to compositions containing them and to their use in the treatment of diseases and conditions for which antagonism of NK1 is beneficial.
    • 式(I)化合物或其药学上可接受的盐,其中R是氢或C 1-4烷基; R 1是氢,C 1-4烷基,C(O)OH,C(O)NH 2或(C 1-4亚烷基)R 10; R 2和R 3独立地是氢,C 1-4烷基或R 2与R 3一起并与它们所连接的碳原子一起形成C 3-8环烷基; R4是C 1-4烷基,C 1-4烷氧基或卤素; R 5和R 7独立地是氢,羟基,卤素,C(O)NH 2,C(O)OH或(C 1-4亚烷基)R 10; R6和R8独立地是氢或卤素; R 9是氢,(C 1-4亚烷基)R 10,C(O)NH 2,C(O)OH或R 9与R一起形成任选地含有另外选自氧,硫或氮的杂原子的6元杂环; R 10是氢,卤素,羟基,C(O)NH 2,C(O)NH(C 1-4烷基),C(O)N(C 1-4烷基)2或C(O) n为O,1或2.制备方法,含有它们的组合物及其用于治疗NK1拮抗作用的疾病和病症的用途。